Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California. more
Time Frame | ALXO | Sector | S&P500 |
---|---|---|---|
1-Week Return | 3.61% | -1.95% | 0.69% |
1-Month Return | 16.22% | -3.36% | 1.53% |
3-Month Return | -18.1% | -6.93% | 11.27% |
6-Month Return | -80.16% | -1.83% | 13.49% |
1-Year Return | -86.24% | 8.53% | 31.62% |
3-Year Return | -94.36% | 7.58% | 30.33% |
5-Year Return | -94.27% | 44.7% | 93.83% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 4.80M | 1.18M | - | - | - | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":24.65,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 4.36M | 1.07M | 736.00K | 1.47M | 836.00K | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":24.66,"profit":true},{"date":"2021-12-31","value":16.88,"profit":true},{"date":"2022-12-31","value":33.62,"profit":true},{"date":"2023-12-31","value":19.17,"profit":true}] |
Gross Profit | 436.00K | 107.00K | (736.00K) | (1.47M) | (836.00K) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":24.54,"profit":true},{"date":"2021-12-31","value":-168.81,"profit":false},{"date":"2022-12-31","value":-336.24,"profit":false},{"date":"2023-12-31","value":-191.74,"profit":false}] |
Gross Margin | 9.09% | 9.05% | - | - | - | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":99.58,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 19.62M | 43.77M | 83.56M | 127.44M | 170.28M | [{"date":"2019-12-31","value":11.52,"profit":true},{"date":"2020-12-31","value":25.71,"profit":true},{"date":"2021-12-31","value":49.07,"profit":true},{"date":"2022-12-31","value":74.84,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (19.18M) | (43.66M) | (83.56M) | (127.44M) | (170.28M) | [{"date":"2019-12-31","value":-1918300000,"profit":false},{"date":"2020-12-31","value":-4366300000,"profit":false},{"date":"2021-12-31","value":-8355500000,"profit":false},{"date":"2022-12-31","value":-12743600000,"profit":false},{"date":"2023-12-31","value":-17027800000,"profit":false}] |
Total Non-Operating Income/Expense | (47.00K) | (2.65M) | 58.00K | 8.30M | 18.56M | [{"date":"2019-12-31","value":-0.25,"profit":false},{"date":"2020-12-31","value":-14.26,"profit":false},{"date":"2021-12-31","value":0.31,"profit":true},{"date":"2022-12-31","value":44.71,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (19.21M) | (45.50M) | (83.48M) | (123.42M) | (160.81M) | [{"date":"2019-12-31","value":-1920900000,"profit":false},{"date":"2020-12-31","value":-4549900000,"profit":false},{"date":"2021-12-31","value":-8348400000,"profit":false},{"date":"2022-12-31","value":-12341800000,"profit":false},{"date":"2023-12-31","value":-16080500000,"profit":false}] |
Income Taxes | 34.00K | 241.00K | (21.00K) | 64.00K | - | [{"date":"2019-12-31","value":14.11,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-8.71,"profit":false},{"date":"2022-12-31","value":26.56,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | (19.24M) | (45.74M) | (83.46M) | (123.48M) | - | [{"date":"2019-12-31","value":-1924300000,"profit":false},{"date":"2020-12-31","value":-4574000000,"profit":false},{"date":"2021-12-31","value":-8346300000,"profit":false},{"date":"2022-12-31","value":-12348200000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (19.24M) | (45.74M) | (83.46M) | (123.48M) | (160.81M) | [{"date":"2019-12-31","value":-1924300000,"profit":false},{"date":"2020-12-31","value":-4574000000,"profit":false},{"date":"2021-12-31","value":-8346300000,"profit":false},{"date":"2022-12-31","value":-12348200000,"profit":false},{"date":"2023-12-31","value":-16080500000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (19.24M) | (45.74M) | (83.46M) | (123.48M) | (160.81M) | [{"date":"2019-12-31","value":-1924300000,"profit":false},{"date":"2020-12-31","value":-4574000000,"profit":false},{"date":"2021-12-31","value":-8346300000,"profit":false},{"date":"2022-12-31","value":-12348200000,"profit":false},{"date":"2023-12-31","value":-16080500000,"profit":false}] |
EPS (Diluted) | - | (4.47) | (2.06) | (3.03) | (3.75) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-446.85,"profit":false},{"date":"2021-12-31","value":-206,"profit":false},{"date":"2022-12-31","value":-303,"profit":false},{"date":"2023-12-31","value":-375,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
ALXO | |
---|---|
Cash Ratio | 4.59 |
Current Ratio | 4.82 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ALXO | |
---|---|
ROA (LTM) | -49.25% |
ROE (LTM) | -98.94% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ALXO | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.26 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.74 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ALXO | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 5906.24 |
P/B | 0.62 |
Price/FCF | NM |
EV/R | 4254.36 |
EV/Ebitda | NM |
Alx Oncology Holdings (ALXO) share price today is $1.72
Yes, Indians can buy shares of Alx Oncology Holdings (ALXO) on Vested. To buy Alx Oncology Holdings from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ALXO stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Alx Oncology Holdings (ALXO) via the Vested app. You can start investing in Alx Oncology Holdings (ALXO) with a minimum investment of $1.
You can invest in shares of Alx Oncology Holdings (ALXO) via Vested in three simple steps:
The 52-week high price of Alx Oncology Holdings (ALXO) is $17.82. The 52-week low price of Alx Oncology Holdings (ALXO) is $1.19.
The price-to-earnings (P/E) ratio of Alx Oncology Holdings (ALXO) is
The price-to-book (P/B) ratio of Alx Oncology Holdings (ALXO) is 0.62
The dividend yield of Alx Oncology Holdings (ALXO) is 0.00%
The market capitalization of Alx Oncology Holdings (ALXO) is $95.47M
The stock symbol (or ticker) of Alx Oncology Holdings is ALXO